Analyst Downgrades: HP, Marvell Technology, and Otonomy

Analysts downwardly revised their ratings on Hewlett-Packard Company (NYSE:HPQ), Marvell Technology Group Ltd. (NASDAQ:MRVL), and Otonomy Inc (NASDAQ:OTIC)

May 22, 2015 at 9:39 AM
facebook twitter linkedin

Analysts are weighing in on computer issue Hewlett-Packard Company (NYSE:HPQ), semiconductor concern Marvell Technology Group Ltd. (NASDAQ:MRVL), and biopharmaceutical firm Otonomy Inc (NASDAQ:OTIC). Here's a quick roundup of today's bearish brokerage notes on HPQ, MRVL, and OTIC.

  • HPQ received price-target cuts from Cantor (to $33), RBC (to $37), and BMO (to $38), after the firm posted mixed results for its fiscal second quarter, and said it will endure around $400 million in costs when it splits into two separate companies in November. These aren't the first headlines HPQ has made this week, with yesterday's M&A news providing Hewlett-Packard Company shares with a quick shot in the arm. Longer term, though, the stock has been a laggard, shedding more than 14% of its value year-to-date. Another round of downwardly revised price targets could be in the pipeline, should HPQ continue to struggle. The security's average 12-month price target of $40.40 represents expected upside of 17.4% to HPQ's present price of $34.42.
  • A number of brokerage firms chimed in on MRVL, following the company's first-quarter revenue miss. Additionally, Marvell Technology Group Ltd. offered up a lower-than-expected current-quarter forecast and announced the retirement of Chief Financial Officer Mike Rashkin. Included in the bunch was Credit Suisse, which cut its price target to $13 from $16, and Jefferies, which reduced its target price to $14 from $15. Raymond James, meanwhile, boosted its price target to $16 from $15 -- a 14.7% premium to the stock's current perch at $13.95. Against this backdrop, MRVL is down 2.9% at the open, which could prompt some option bulls to hit the bricks. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), MRVL's 50-day call/put volume ratio of 11.52 sits in the 94th annual percentile. In other words, calls have been bought to open over puts with more rapidity just 6% of the time within the past year.
  • OTIC plunged 18.4% out of the gate to $25.35, after the company's experimental ear drug, OTO-104, failed to meet the main goal of its mid-stage trial. Adding to the bearish bias is a downgrade to "neutral" from "overweight" and price-target cut to $30 from $42 at J.P. Morgan Securities. Bernstein also weighed in on Otonomy Inc, reducing its target price to $30 from $34. Heading into today's session, the stock had already lost over a quarter of its value since topping out at a record high of $41.99 in mid-March, and short sellers have likely been cheering. At present, more than 10% of the equity's float is sold short.



Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners